Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Aptinyx Inc.
Aptinyx Inc. News
Aptinyx Inc. Quantitative Score
About Aptinyx Inc.
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Aptinyx Inc. Earnings & Revenue
Aptinyx Inc. Financials
Table Compare
Compare APTX metrics with: | |||
|---|---|---|---|
Earnings & Growth | APTX | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | APTX | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | APTX | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | APTX | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Aptinyx Inc. Income
Aptinyx Inc. Balance Sheet
Aptinyx Inc. Cash Flow
Aptinyx Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Buy |
| Price/Earnings Ratio | Neutral |
| Price/Book Ratio | Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Aptinyx Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Aptinyx Inc. Executives
| Name | Role |
|---|---|
| Dr. Norbert G. Riedel | Executive Chairman |
| Dr. Andrew D. Kidd B.M. B.Ch., M.D. | Interim Principal Executive Officer, Principal Financial Officer & Principal Accounting Officer |
| Mr. Ashish Khanna | Chief Financial Officer & Chief Bus. Officer |
| Ms. Molly Dir | Vice President of Human Resources |
| Mr. Patrick Flavin | Senior Manager of Corporate Development & Investor Relations |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Norbert G. Riedel | Executive Chairman | 1958 | 851.45K | |
| Dr. Andrew D. Kidd B.M. B.Ch., M.D. | Interim Principal Executive Officer, Principal Financial Officer & Principal Accounting Officer | 1976 | 736.6K | |
| Mr. Ashish Khanna | Chief Financial Officer & Chief Bus. Officer | Male | 1976 | 603.76K |
| Ms. Molly Dir | Vice President of Human Resources | Female | -- | |
| Mr. Patrick Flavin | Senior Manager of Corporate Development & Investor Relations | Male | -- |
Aptinyx Inc. Insider Trades
| Date | 3 Jan |
| Name | KHANNA ASHISH |
| Role | CFO AND CBO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 375000 |
| Date | 3 Jan |
| Name | RIEDEL NORBERT G |
| Role | EXECUTIVE CHAIRMAN OF THE BOD |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 420000 |
| Date | 3 Jan |
| Name | KIDD ANDREW |
| Role | PRESIDENT AND CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 700000 |
| Date | 26 May |
| Name | Koppel Adam |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40000 |
| Date | 26 May |
| Name | Koppel Adam |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 40000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 3 Jan | KHANNA ASHISH | CFO AND CBO | Acquired | A-Award | 375000 |
| 3 Jan | RIEDEL NORBERT G | EXECUTIVE CHAIRMAN OF THE BOD | Acquired | A-Award | 420000 |
| 3 Jan | KIDD ANDREW | PRESIDENT AND CEO | Acquired | A-Award | 700000 |
| 26 May | Koppel Adam | Director | Acquired | A-Award | 40000 |
| 26 May | Koppel Adam | Director, 10 percent owner | Acquired | A-Award | 40000 |